Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Abiraterone Acetate in Combination With Tildrakizumab
NCT04458311 · Institute of Cancer Research, United Kingdom · PHASE1/PHASE2 · terminated · last registry update 2024-04-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funder decided that response outcomes to date did not support continuation of the study.” | – | Registry record, Institute of Cancer Research, United Kingdom |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP17A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-13Also stopped (terminated): Centre hospitalier de l'Université de Montréal (CHUM), Cabazitaxel plus prednisone + Docetaxel plus prednisone (NCT03764540)
- 2025-04-08Results posted on the registry: Opna Bio LLC, PLX2853 20 mg + Olaparib (NCT04556617)
- 2025-04-08Also stopped (terminated): Opna Bio LLC, PLX2853 20 mg + Olaparib (NCT04556617)
- 2025-03-06Results posted on the registry: Eli Lilly and Company, Abemaciclib + Placebo (NCT03706365)
- 2025-03-03Phase 3 first posted: Novartis Pharmaceuticals, AAA817 + ARPI (NCT06855277)
- 2025-02-28Also stopped (terminated): ESSA Pharmaceuticals, EPI-7386 (QD) + EPI-7386 (BID) (NCT04421222)
- 2025-02-03Also stopped (terminated): Janssen Research & Development, LLC, EPI-7386 + Abiraterone Acetate (NCT05295927)
- 2025-01-27Results posted on the registry: M.D. Anderson Cancer Center, Abiraterone Acetate + Prednisone (NCT01254864)
- 2025-01-10Phase 3 first posted: Ding-Wei Ye, Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT + Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT (NCT06768255)
- 2025-01-08Phase 3 first posted: Celgene, BMS-986365 + Enzalutamide (NCT06764485)
- 2024-12-11Results posted on the registry: MedSIR, radium-223 (NCT03002220)
- 2024-12-10Results posted on the registry: Memorial Sloan Kettering Cancer Center, Abiraterone acetate 1000 mg po daily + Cabazitaxel 25 mg/m2 IV (NCT02218606)
- 2024-11-18Phase 3 first posted: Amgen, Xaluritamig + Abiraterone (NCT06691984)
- 2024-11-07Results posted on the registry: Cardiff Oncology, Onvansertib + Abiraterone (NCT03414034)
- 2024-10-21Phase 3 first posted: Emory University, Abiraterone Acetate + Bicalutamide (NCT06650579)
- 2024-10-17Also stopped (terminated): DisperSol Technologies, LLC, Abiraterone Acetate + Prednisone 5Mg Tab (NCT04291664)
- 2024-09-25Results posted on the registry: Medical University of South Carolina, Opaganib + Abiraterone (NCT04207255)
- 2024-09-19Phase 3 first posted: Canadian Cancer Trials Group, Abiraterone + Enzalutamide (NCT06592924)
- 2024-09-19Also stopped (withdrawn): Baptist Health South Florida, 177Lu-PSMA-617 + Niraparib abiraterone acetate (NCT06329830)
- 2024-09-19Results posted on the registry: Dana-Farber Cancer Institute, Prednisone + Apalutamide (NCT03777982)
- 2024-09-19Also stopped (terminated): Dana-Farber Cancer Institute, Prednisone + Apalutamide (NCT03777982)
- 2024-09-05Phase 3 first posted: Universitaire Ziekenhuizen KU Leuven, a drug against CYP17A1 (NCT06585007)
- 2024-08-13Phase 3 first posted: Pfizer, PF-06821497 + Docetaxel (NCT06551324)
- 2024-08-09Also stopped (terminated): Biosplice Therapeutics, Inc., SM08502 + Abiraterone (NCT05084859)
- 2024-07-25Phase 3 first posted: Telix Pharmaceuticals (Innovations) Pty Limited, 177Lu-TLX591 + Enzalutamide (NCT06520345)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision